Anmeldung zur Tagung
Registration
Grußwort
Invitation
Themen
Topics
Allgemeiner Ablauf
General overview
Wissenschaftliches Programm
Scientific program
Kurse
Courses
Symposien
Symposiums
Frühstück mit Spezialisten
Breakfast with specialists
Arzthelferinnen-Fortbildung
Rahmenprogramm
Social program
DOG Information
DOG Information
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Ausstellerliste
Exhibitors
Sponsoren
Sponsors
Teilnahmegebühren
Registration fees
Impressum
Long-term Results of Immunosuppressive Therapy with Mycophenolate Mofetil (CellCept®) for Keratoplasty in High-risk Patients
Soares-Wulf A., Aboalchamat B., Krüger R., Richard G., Engelmann K.
University Eye Clinic Eppendorf, Martinistr. 52, D20246 Hamburg
Introduction: In a pilot study we investigated the potential of
mycophenolate mofetil as an immunosuppressive agent with mild side effects
for prevention of transplant rejection in high risk patients for keratoplasty.
The long-term results of this study will be presented in this abstract.
Methods: In this study, 34 patients (mean age: 55.2 y, range: 22-86
y) were treated with mycophenolate mofetil. Mean follow-up duration was
15.8 mo (range: 6-38 mo). The immunosuppression was initialised with systemic
steroids. Criteria of high-risk for keratoplasty included re-keratoplasty,
a Chaud keratoplasty, vascularisation of host cornea, and status post
herpetic keratitis. An additional criterium for high-risk keratoplasty
was atopic dermatitis in 4 patients.
Results: 31 from 34 patients (91%) showed no rejection episodes
during the follow-up. 3 patients had a transplant failure because of break-up
of therapy, non-compliance and others. During the first weeks after starting
the therapy with mycophenolate mofetil, 9 patients suffered from reversible
side effects. Gastrointestinal problems were the most frequent reported
side effects. 2 patients suffered from severe side effects, so that the
immunosuppression with mycophenolate mofetil was terminated. No adverse
effects were reported in 25 patients.
Conclusion: Mycophenolate mofetil presents a new immunosuppressant
for the prevention of transplant rejection in high-risk patients with
mild side effects. A consecutive multi-center study was initialised in
Germany.